Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
HRTX Stock Chart & Stats
$1.27
-$0.05(-2.96%)
At close: 4:00 PM EST
$1.27
-$0.05(-2.96%)
Day’s Range― - ―
52-Week Range$1.00 - $2.68
Previous CloseN/A
Volume327.52K
Average Volume (3M)2.08M
Market Cap
$214.53M
Enterprise Value$307.46M
Total Cash (Recent Filing)$55.49M
Total Debt (Recent Filing)$140.44M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 04, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding183,362,520
10 Day Avg. Volume2,026,155
30 Day Avg. Volume2,075,811
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-6.93
Price to Sales (P/S)1.62
P/FCF Ratio-9.62
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue1.98
Enterprise Value/Gross Profit2.77
Enterprise Value/Ebitda-119.77
Forecast
1Y Price Target
$4.50Price Target Upside254.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$156.48M
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesThe NOPAIN Act is expected to improve access and coverage across government and commercial payers, serving as a tailwind for Zynrelef.
Revenue GrowthZynrelef revenue growth is driven by demand, improved access, and the transition to Vial Access Needle, which enhances user experience and adoption.
Sales Team ImpactAponvie revenue grew significantly, and the fully trained and dedicated sales team is anticipated to drive further growth.
Bears Say
Competitive PressureCinvanti sales are stable but face ongoing competitive pressure, which may lead to price concessions or account losses.
Financial PerformanceHRTX missed on GAAP EPS due to the loss on extinguishment of debt charge related to the balance sheet cleanup announced earlier this year.
Market CompetitionOncology franchise revenue experienced a modest decline, with plans to wind down Sustol commercialization due to increased market competition.
Heron Therapeutics News
HRTX FAQ
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $1.00 and its highest was $2.68 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $214.53M.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is Mar 04, 2026 which is in 89 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Nov 04, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.015 by -$0.085.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -0.02.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 183,362,520 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.015. Following the earnings report the stock price went down -3.39%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Currently, no hedge funds are holding shares in HRTX
Heron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (254.33% Upside)
$4.50 (254.33% Upside)
Blogger Sentiment
Neutral
HRTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.76%
Trailing 12-Months
Company Description
Heron Therapeutics
Heron Therapeutics, Inc. (HRTX) is a biotechnology company focused on developing and commercializing innovative therapeutics for patients suffering from pain and cancer. The company operates primarily in the pharmaceutical sector, specializing in the development of products that address unmet medical needs, particularly in the areas of post-operative pain management and cancer treatment. Heron’s core products include its proprietary formulations designed to provide improved efficacy and safety profiles compared to existing treatments.
HRTX Company Deck
HRTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in key product lines such as ZYNRELEF and APONVIE, successful completion of financing, and the positive impact of new initiatives. However, challenges remain with declining SUSTOL sales, a decrease in gross margin, and a reported net loss due to debt extinguishment. Overall, the company appears to be on a positive trajectory but faces some financial challenges.View all HRTX earnings summariesHRTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(254.33% Upside)
Technical Analysis
Ocugen
―
Benitec Biopharma
―
Kodiak Sciences
―
Sagimet Biosciences, Inc. Class A
―
Neumora Therapeutics, Inc.
―
Ownership Overview
21.91% Insiders
8.02% Mutual Funds
49.77% Other Institutional Investors
12.34% Public Companies and
Individual Investors